These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 25326838)
41. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication. Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049 [TBL] [Abstract][Full Text] [Related]
43. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Bihan H; Ng WL; Magliano DJ; Shaw JE Diabetes Res Clin Pract; 2016 Nov; 121():27-34. PubMed ID: 27622682 [TBL] [Abstract][Full Text] [Related]
44. Drug discovery approaches targeting the incretin pathway. Deng X; Tavallaie MS; Sun R; Wang J; Cai Q; Shen J; Lei S; Fu L; Jiang F Bioorg Chem; 2020 Jun; 99():103810. PubMed ID: 32325333 [TBL] [Abstract][Full Text] [Related]
45. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence. Kawanami D; Matoba K; Sango K; Utsunomiya K Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245 [TBL] [Abstract][Full Text] [Related]
46. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model. Voronova V; Zhudenkov K; Penland RC; Boulton DW; Helmlinger G; Peskov K Diabetes Obes Metab; 2018 Aug; 20(8):2034-2038. PubMed ID: 29663628 [TBL] [Abstract][Full Text] [Related]
47. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Drab SR Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049 [TBL] [Abstract][Full Text] [Related]
48. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Siddiqui NI Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763 [TBL] [Abstract][Full Text] [Related]
49. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Nauck MA Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578 [TBL] [Abstract][Full Text] [Related]
50. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus. Dahiya L; Kaur R; Kumar R; Kumar M; Palta K Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118 [TBL] [Abstract][Full Text] [Related]
51. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver? van Baar MJB; van Raalte DH Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285 [TBL] [Abstract][Full Text] [Related]
52. Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus. Yaribeygi H; Atkin SL; Montecucco F; Jamialahmadi T; Sahebkar A Biomed Res Int; 2021; 2021():8163153. PubMed ID: 34471642 [TBL] [Abstract][Full Text] [Related]
53. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. Martin CL Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067 [TBL] [Abstract][Full Text] [Related]